NASDAQ:ALKS
Alkermes plc Stock News
$23.40
+0.190 (+0.82%)
At Close: May 31, 2024
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
04:00pm, Thursday, 04'th Feb 2021
DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company'
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
08:00am, Monday, 04'th Jan 2021
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, pa
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
07:00am, Tuesday, 29'th Dec 2020
DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Application (NDA)
Alkermes (ALKS) Moves to Buy: Rationale Behind the Upgrade
12:47pm, Tuesday, 22'nd Dec 2020
Alkermes (ALKS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Alkermes Shares Jumped Higher Today
02:58pm, Thursday, 10'th Dec 2020
The biotech has a plan to increase profitability.
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
10:24am, Thursday, 29'th Oct 2020
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulti
Entera Osteoporosis Trial, And Other News: The Good, Bad And Ugly Of Biopharma
06:48am, Monday, 24'th Aug 2020
Entera Bio reports encouraging data from osteoporosis trial. Alkermes progresses Phase 2 trial for ALKS 4230.
Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of
Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, American Jour
ANIK or ALKS: Which Is the Better Value Stock Right Now?
03:40pm, Wednesday, 05'th Aug 2020
ANIK vs. ALKS: Which Stock Is the Better Value Option?
10 Biggest Biotechnology Companies
11:32pm, Thursday, 30'th Jul 2020
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
03:08pm, Thursday, 30'th Jul 2020
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
Estimating The Intrinsic Value Of Alkermes plc (NASDAQ:ALKS)
12:08pm, Thursday, 30'th Jul 2020
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alkermes plc...
Alkermes PLC (ALKS) Q2 2020 Earnings Call Transcript
09:30pm, Wednesday, 29'th Jul 2020
ALKS earnings call for the period ending June 30, 2020.
Alkermes plc (ALKS) CEO Richard Pops on Q2 2020 Results - Earnings Call Transcript
04:20pm, Wednesday, 29'th Jul 2020
Alkermes plc (NASDAQ:ALKS) Q2 2020 Results Conference Call July 29, 2020 08:00 ET Company Participants Sandra Coombs - Vice President, Investor Relations Richard Pops - Chairman and Chief Executive Of
